Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

4.960 +0.150 (+3.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 468,391
Open 4.760
Bid (Size) 4.710 (2)
Ask (Size) 4.960 (1)
Prev. Close 4.810
Today's Range 4.690 - 4.970
52wk Range 2.100 - 13.52
Shares Outstanding 44,784,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire

Performance

YTD
-23.6%
-23.6%
1 Month
-31.4%
-31.4%
3 Month
-6.6%
-6.6%
6 Month
+48.9%
+48.9%
1 Year
-54.6%
-54.6%

More News

Read More
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
From Verastem Oncology
Via Business Wire
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?
Via Benzinga
Exposures Product Safety
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
From Applied Therapeutics
Via GlobeNewswire
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
From Verastem Oncology
Via Business Wire

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 4.960
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 04/16/25 04:00 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 222.13M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 222M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.